Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1

Putri Cahaya Situmorang, Syafruddin Ilyas, Rony Abdi Syahputra, Reka Mustika Sari, Alexander Patera Nugraha, Alek Ibrahim

Open source

DOI: 10.3389/fphar.2024.1345645
Published: 2024-02-27
Container: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

serious concern Score 29/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
serious concernRetraction Watch retraction: 1 retraction notice matched this DOI. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2024.1345645,
  title = {Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1},
  author = {Putri Cahaya Situmorang and Syafruddin Ilyas and Rony Abdi Syahputra and Reka Mustika Sari and Alexander Patera Nugraha and Alek Ibrahim},
  year = {2024},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2024.1345645},
  url = {https://doi.org/10.3389/fphar.2024.1345645}
}

RIS

TY  - JOUR
TI  - Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1
AU  - Putri Cahaya Situmorang
AU  - Syafruddin Ilyas
AU  - Rony Abdi Syahputra
AU  - Reka Mustika Sari
AU  - Alexander Patera Nugraha
AU  - Alek Ibrahim
PY  - 2024
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2024.1345645
UR  - https://doi.org/10.3389/fphar.2024.1345645
ER  -

APA

Situmorang, P. C., Ilyas, S., Syahputra, R. A., Sari, R. M., Nugraha, A. P., & Ibrahim, A. (2024). Rhodomyrtus tomentosa as a new anticancer molecular strategy in breast histology via Her2, IL33, EGFR, and MUC1. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2024.1345645

Source records

crossref · retrieved 2026-09-25T01:31:18.889Z